Phase 4
Completed N=92
Ideal Steroids for Asthma Treatment in the PICU
Asthma Childhood
Source: ClinicalTrials.gov NCT03900624 ↗
Enrolled (actual)
92
Serious AEs
0.0%
Results posted
Aug 2022
Primary outcomePrimary: Length of Stay — 2.9; 2.9 days — p=0.632
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Determine if differences in (1) pediatric intensive care unit length of stay, (2) continuous nebulized albuterol duration, and (3) a composite outcome of advanced asthma therapy incidence including use of non-invasive ventilation (NIV), terbutaline, inhaled helium and mechanical ventilation between cohorts of children admitted with status asthmaticus to the PICU treated with either IV dexamethasone (DM) or methylprednisolone (MP).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Length of Stay |
2.9; 2.9 | 0.632 |
| SECONDARY Duration of Continuous Nebulized Albuterol |
1; 0.8 | 0.725 |
Eligibility Criteria
Inclusion Criteria
- Inclusion criteria are children 5 to 17 years of age with primary admission diagnoses of acute asthma exacerbation or status asthmaticus admitted to the PICU
Exclusion Criteria
- children with existing tracheostomy, cystic fibrosis, and pulmonary hypertension
Data sourced from ClinicalTrials.gov (NCT03900624). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.